# US 10,309,965 B2 · Method and kit for determining the probability that a patient will develop a severe case of dengue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,309,965 B2
- Document ID: US10309965B2
- Status: Granted
- Kind: B2
- Application number: 15/912,730
- Filed: 2018-03-06
- Published: 2018-07-12
- Granted: 2019-06-04
- Earliest claimed: 2014-02-18
- Assignees: Biomerieux
- Applicants: Biomerieux
- Inventors: Frédéric Bedin; Romain Fragnoud
- Web page: https://patentgrep.com/patent/US10309965B2

## CPC

- G01N 33/56983: {Viruses}
- G01N 2333/185: Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
- G01N 2333/521: Chemokines
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A kit for determining whether a patient will develop severe dengue includes a binding partner for platelet factor 4 and a binding partner for at least one member selected from the group consisting of dengue virus NS1 protein, olfactomedin 4, and α2-macroglobulin. The kit may further include a label reagent capable of generating a detectable signal.

## Claims

### Claim 1

A kit for determining whether a patient will develop severe dengue, comprising:
a binding partner for platelet factor 4; and
a binding partner for at least one member selected from the group consisting of dengue virus NS1 protein, olfactomedin 4, and α2-macroglobulin.

### Claim 2 (depends on 1)

The kit of claim 1, further comprising:
a label reagent capable of generating a detectable signal.

### Claim 3 (depends on 1)

The kit of claim 1, comprising the binding partner for dengue virus NS1 protein.

### Claim 4 (depends on 1)

The kit of claim 1, comprising the binding partner for olfactomedin 4.

### Claim 5 (depends on 1)

The kit of claim 1, comprising the binding partner for α2-macroglobulin.

### Claim 6 (depends on 1)

The kit of claim 1, comprising the binding partners for dengue virus NS1 protein and olfactomedin 4.

### Claim 7 (depends on 1)

The kit of claim 1, comprising the binding partners for dengue virus NS1 protein and α2-macroglobulin.

### Claim 8 (depends on 1)

The kit of claim 1, comprising the binding partners for olfactomedin 4 and α2-macroglobulin.

### Claim 9 (depends on 1)

The kit of claim 1, comprising the binding partners for dengue virus NS1 protein, olfactomedin 4, and α2-macroglobulin.